10 Result(s)

Article

Effect of Tezepelumab on Lung Function in Patients With Severe, Uncontrolled Asthma in the Phase 3 NAVIGATOR Study

Severe asthma is associated with airway inflammation and airway obstruction. In the phase 3 NAVIGATOR study, tezepelumab treatment significantly improved pre-bronchodilator forced expiratory volume in 1 s (FEV₁) ...

Andrew Menzies-Gow, Christopher S. Ambrose, Gene Colice… in Advances in Therapy (2023)

Article

A Charter to Fundamentally Change the Role of Oral Corticosteroids in the Management of Asthma

Asthma affects 339 million people worldwide, with an estimated 5–10% experiencing severe asthma. In emergency settings, oral corticosteroids (OCS) can be lifesaving, but acute and long-term treatment can produ...

John Haughney, Tonya Winders, Steve Holmes, Pascal Chanez… in Advances in Therapy (2023)

Article

A Renewed Charter: Key Principles to Improve Patient Care in Severe Asthma

Asthma is a heterogenous respiratory disease, usually associated with chronic airway inflammation and hyper-responsiveness, which affects an estimated 339 million people worldwide. Severe asthma affects approx...

Andrew Menzies-Gow, David J. Jackson, Mona Al-Ahmad… in Advances in Therapy (2022)

Article

A Response to: Letter to the Editor Regarding “Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab”

Andrew Menzies-Gow, Flavia L. Hoyte, David B. Price, David Cohen… in Advances in Therapy (2022)

Article

Environmental Sustainability in Respiratory Care: An Overview of the healthCARe-Based envirONmental Cost of Treatment (CARBON) Programme

Faced with the challenges of climate change, countries are seeking to decarbonise their economies. A greater understanding of what comprises the carbon footprint of care in healthcare systems will identify pot...

Alex Wilkinson, Ekaterina Maslova, Christer Janson, Yang Xu… in Advances in Therapy (2022)

Article

Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab

Consensus definitions for clinical remission and super-response were recently established for severe asthma. Benralizumab is an interleukin-5 (IL-5) receptor α-directed monoclonal antibody for severe, uncontro...

Andrew Menzies-Gow, Flavia L. Hoyte, David B. Price, David Cohen… in Advances in Therapy (2022)

Article

Global Quality Standard for Identification and Management of Severe Asthma

Severe asthma is a debilitating, life-threatening disease associated with substantial global morbidity, mortality, and health care resource utilization. Patients may not receive guideline-directed medical care...

John Haughney, Tonya A. Winders, Steve Holmes, Pascal Chanez… in Advances in Therapy (2020)

Article

SABINA: An Overview of Short-Acting β₂-Agonist Use in Asthma in European Countries

Globally, individuals with asthma tend to overrely on short-acting β₂-agonists (SABAs) and underuse inhaled corticosteroids, thereby undertreating the underlying inflammation. Such relief-seeking behavior has bee...

Christer Janson, Andrew Menzies-Gow, Cassandra Nan, Javier Nuevo… in Advances in Therapy (2020)

Article

A Charter to Improve Patient Care in Severe Asthma

Severe asthma is a subtype of asthma that is difficult to treat and control. By conservative estimates, severe asthma affects approximately 5–10% of patients with asthma worldwide. Severe asthma impairs patien...

Andrew Menzies-Gow, G-Walter Canonica, Tonya A. Winders… in Advances in Therapy (2018)

Article

Rapid and Consistent Improvements in Morning PEF in Patients with Severe Eosinophilic Asthma Treated with Mepolizumab

Previous studies showed that mepolizumab significantly reduces exacerbations and oral corticosteroid use in patients with severe eosinophilic asthma. However, early studies reported inconsistent effects on lun...

Hector Ortega, Andrew Menzies-Gow, Jean-Pierre Llanos, Mark Forshag… in Advances in Therapy (2018)